Company intelligence / Profile preview

Ten Sun Pharma

Mumbai, Maharashtra, Indiasunpharma.com ↗

Ownership: Private
Employees: ~41000
Development stage: Other

Overview

Sun Pharma markets over a thousand products worldwide in both generic and specialty segments. It has several late-stage R&D projects including fixed-dose combinations for type II diabetes and licensed immuno-oncology assets. Recent launches include Fexuprazan for erosive esophagitis in India.

Therapeutic areas: NeurologyPsychiatryDermatologyOphthalmologyGastroenterologyEndocrinologyOncologyMen's HealthOtherNephrologyCardiovascular
Modalities: Small moleculeBiologic (including biosimilars)Antibody (monoclonal antibody)PeptidesLiposomal drugsInhalers and nasal sprays (Device/Drug combination)
Industry: Biotech

Partnerships

Philogen S.p.A.Checkpoint Therapeutics acquisition agreementlicensing agreements with Gilead Sciences/Merck for generics access in HIV/COVID‑19 therapies

Beyond the preview

Go deeper on Ten Sun Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ten Sun Pharma.

Explore the full profile